Aktuellt
SENASTE
Redeye retains its positive view of Avensia following a solid Q3 report with a healthy underlying margin. The market is in better shape than last year, but the optimism in H1 2024 softened somewhat in Q3. We will likely leave our forecasts and Base Case largely unchanged.
LÄS MER
